skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Peroxiredoxin 4, A Novel Circulating Biomarker for Oxidative Stress and the Risk of Incident Cardiovascular Disease and All‐Cause Mortality

Journal of the American Heart Association, 2012-10, Vol.1 (5), p.e002956-n/a [Peer Reviewed Journal]

2012 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley‐Blackwell. ;2012 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. 2012 ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/JAHA.112.002956 ;PMID: 23316297

Full text available

Citations Cited by
  • Title:
    Peroxiredoxin 4, A Novel Circulating Biomarker for Oxidative Stress and the Risk of Incident Cardiovascular Disease and All‐Cause Mortality
  • Author: Abbasi, Ali ; Corpeleijn, Eva ; Postmus, Douwe ; Gansevoort, Ron T. ; Jong, Paul E. ; Gans, Rijk O. B. ; Struck, Joachim ; Schulte, Janin ; Hillege, Hans L. ; Harst, Pim ; Peelen, Linda M. ; Beulens, Joline W. J. ; Stolk, Ronald P. ; Navis, Gerjan ; Bakker, Stephan J. L.
  • Subjects: Adult ; Aged ; Biomarkers - blood ; cardiovascular disease ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - mortality ; epidemiology ; Female ; Humans ; Male ; Middle Aged ; mortality ; Netherlands ; Original Research ; oxidative stress ; Oxidative Stress - physiology ; peroxiredoxin 4 ; Peroxiredoxins - blood ; Regression Analysis ; Risk Factors
  • Is Part Of: Journal of the American Heart Association, 2012-10, Vol.1 (5), p.e002956-n/a
  • Description: Background Oxidative stress has been suggested to play a key role in the development of cardiovascular disease (CVD). The aim of our study was to investigate the associations of serum peroxiredoxin 4 (Prx4), a hydrogen peroxide–degrading peroxidase, with incident CVD and all‐cause mortality. We subsequently examined the incremental value of Prx4 for the risk prediction of CVD compared with the Framingham risk score (FRS). Methods and Results We performed Cox regression analyses in 8141 participants without history of CVD (aged 28 to 75 years; women 52.6%) from the Prevention of Renal and Vascular End‐stage Disease (PREVEND) study in Groningen, The Netherlands. Serum Prx4 was measured by an immunoluminometric assay in baseline samples. Main outcomes were: (1) incident CVD events or CVD mortality and (2) all‐cause mortality during a median follow‐up of 10.5 years. In total, 708 participants (7.8%) developed CVD events or CVD mortality, and 517 participants (6.3%) died. Baseline serum Prx4 levels were significantly higher in participants with incident CVD events or CVD mortality and in those who died than in participants who remained free of outcomes (both P<0.001). In multivariable models with adjustment for Framingham risk factors, hazard ratios were 1.16 (95% CI 1.06 to 1.27, P<0.001) for incident CVD events or CVD mortality and 1.17 (95% CI 1.06 to 1.29, P=0.003) for all‐cause mortality per doubling of Prx4 levels. After the addition of Prx4 to the FRS, the net reclassification improvement was 2.7% (P=0.01) using 10‐year risk categories of CVD. Conclusions Elevated serum Prx4 levels are associated with a significantly higher risk of incident CVD events or CVD mortality and all‐cause mortality after adjustment for clinical risk factors. The addition of Prx4 to the FRS marginally improved risk prediction of future CVD.
  • Publisher: England: Blackwell Publishing Ltd
  • Language: English
  • Identifier: ISSN: 2047-9980
    EISSN: 2047-9980
    DOI: 10.1161/JAHA.112.002956
    PMID: 23316297
  • Source: Open Access: Wiley Blackwell Open Access Journals
    PubMed Central (Open access)
    DOAJ Directory of Open Access Journals
    Geneva Foundation Free Medical Journals at publisher websites
    MEDLINE
    ROAD: Directory of Open Access Scholarly Resources

Searching Remote Databases, Please Wait